Attenuation of β-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers

Biochimica et Biophysica Acta - General Subjects

Volumn 1760, Issue 12, 2006, Pages 1802-1809

  Patel, Dhara ^a   Henry, James ^a   Good, Theresa ^a  

^a University of Marylandw Baltimore County   (United States)

Author keywords

Alzheimer's disease; Amyloid; Dendrimer; Sialic acid; Toxicity

Indexed keywords

AMYLOID BETA PROTEIN; DENDRIMER; POLYAMIDOAMINE; POLYMER; SIALIC ACID;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROTOXICITY; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; CELL LINE, TUMOR; DENDRIMERS; FLOW CYTOMETRY; HUMANS; N-ACETYLNEURAMINIC ACID;

EID: 33750626825     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2006.08.008     Document Type: Article

References (46)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the U.S. population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
2. Ernst R.L., and Hay J.W. The U.S. economic and social costs of alzheimer's disease revisited. Am. J. Public Health 84 (1994) 1261-1264
3. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 53 (1994) 438-447
4. Seilheimer B., Bohrmann B., Bondolfi L., Muller F., Stuber D., and Dobeli H. The toxicity of the Alzheimer's b-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 119 (1997) 59-71
5. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induces acute electrophysical changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
6. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., Christie G., Davis J.B., George A., Karran E.H., and Howlett D.R. Fractionation and charecterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide. Biochem. J. 348 (2000) 137-144
7. Gelinas D., DaSilva K., Fenili D., George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. 101 (2001) 14657-14662
8. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., De Quervain D., Hofmann J., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against β-amyloid slow cognitive decline in alzheimer's disease. Neuron 38 (2003) 547-554
9. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16 (2004) 599-606
10. Matsuoka Y., Saito M., LaFrancois Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lmere C., and Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23 (2003) 29-33
11. Hertel C., Terzi E., Hauser N., Jakob-Rotne R., Seelig J., and Kemp J.A. Inhibition of the electrostatic interaction between β-amyloid peptide and membranes prevents β-amyloid-induced toxicity. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9412-9416
12. Wang S., Rymer D., and Good T. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of β-amyloid peptides. J. Biol. Chem. 276 (2001) 42027-42034
13. Avdulov N.A., Chochina S.V., Igbavboa U., Warden C.S., Vassiliev A.V., and Wood W.G. Lipid binding to amyloid β-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69 (1997) 1746-1752
14. Choo-Smith L., Garzon-Rodriguez W., Glabe C.G., and Surewicz W.K. Acceleration of amyloid fibril formation by specific binding of Aβ(1-40) peptide of ganglioside containing vesicles. J. Biol. Chem. 272 (1997) 22987-22990
15. Kakio A., Nishimoto S.I., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276 (2001) 24985-24990
16. Ariga T., and Yu R. GM-1 inhibits amyloid β-protein-induced cytokine release. Neurochem. Res. 24 (1999) 219-226
17. Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., and Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid β-protein. Arch. Biochem. Biophys. 388 (2001) 225-230
18. McLaurin J., and Chakrabartty A. Membrane disruption by Alzheimer β-amyloid peptides mediated though specific binding to either phospholipids of gangliosides. J. Biol. Chem. 271 (1996) 26482-26489
19. McLaurin J., Franklin T., Fraser P., and Chakrabartty A. Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides. J. Biol. Chem. 273 (1998) 4506-4515
20. Matsuzaki K., and Horikiri C. Interactions of amyloid β-Peptide (1-40) with ganglioside-containing membranes. Biochemistry 38 (1999) 4137-4142
21. Yanagisawa K., Odaka A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995) 1062-1066
22. Wakabayashi M., Okada T., Kozutsumi Y., and Matsuzaki K. GMI ganglioside-mediated accumulation of amyloid β-protein on cell membranes. Biochem. Biophys. Res. Comm. 328 (2005) 1019-1023
23. Kakio A., Yano Y., Takai D., Kuroda Y., Matsumoto O., Kozutsumi K., and Matsuzaki K. Interaction between amyloid β-protein aggregates and membranes. J. Peptide Sci. 10 (2004) 612-621
24. Lee S., Carson K., Rice-Ficht A., and Good T. Hsp20, a novel α-crystallin, prevents Aβ fibril formation and toxicity. Protein Sci. 14 (2005) 593-691
25. Rymer D., and Good T. The role of G protein activation in the toxicity of amyloidogenic Abeta-(1-40), Abeta-(25-35), and bovine calcitonin. J. Biol. Chem. 276 (2001) 2523-2530
26. Warren L. The thiobarbituric acid assay of sialic acids. J. Biochem. Chem. 234 (1959) 1971-1975
27. van Engel M., Ramaekers C.S., Schutte B., and Reutelingsperger C.P.M. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24 (1996) 131-139
28. Reuter J., Myc A., Hayes M., Gan Z., Roy R., Qin D., Yin R., Piehler L.T., Esfand R., Tomalia D.A., and Baker J.R. Inhibition of viral adhesion and infection by Sialic acid-conjugated dendritic polymers. Bioconjug. Chem. 10 (1999) 271-278
29. Pritchett T., and Paulson J. Basis for the potent inhibition of influenza virus infection by Equine and guinea pig α2-macroglobulin. J. Biol. Chem. 264 (1989) 9850-9858
30. Landers J., Cao Z., and Lee I. Prevention of influenza pneumonitis by Sialic acid-conjugated dendritic polymers. J. Infect. Dis. 186 (2002) 1222-1230
31. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., and Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24 (2003) 1121-1131
32. Lees W.J., Spaltenstein A., Kingery-Wood J.E., and Whitesides J.M. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by Influenza a virus: multivalency and steric stabilization of particulate biological systems. J. Med. Chem. 37 (1994) 3419-3433
33. S. Prusiner, S. Supattapone, M. Scott, Method of Sterilizing, US Patent: 6 (2003) 517,855.
34. Kayed R., Head E., Thompson J., McIntire T., Milton S., Cotman C., and Glabe C. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
35. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T., Rozovsky I., Trommer B., Viola K., Wals P., Zhang C., Finch C., and Drafft G.A. Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. PNAS 95 (1998) 6448-6453
36. Wang S., Becerra-Arteaga A., and Good T. Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol. Bioeng. 80 (2002) 50-59
37. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
38. McMasters M.J., Hammer R.P., and McCarley R.L. Surface-induced aggregation of beta amyloid peptide by co-substituted alkanethiol monolayers supported on gold. Langmuir 21 (2005) 4464-4470
39. Yamamoto N., Igbabvoa U., Shimada Y., Ohno-Iwashita Y., Kobayashi M., Wood W., Fujita S., and Yanagisawa K. Accelerated Aβ aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569 (2004) 135-139
40. Blumberg P. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res. 48 (1988) 1-8
41. Etcheberringaray R., Tan M., Dewachtert I., Kuiperi C., Van der Auwera I., Wera S., Qiao L., Bank B., Nelson T., Kozikowski A., Van Leuven F., and Alkon D. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. 101 (2004) 11141-11146
42. Ghanta J., Shen C., Kiessling L., and Murphy R.M. A strategy for designing inhibitors of β-amyloid toxicity. J. Biol. Chem. 271 (1996) 29525-29528
43. Blanchard B., Chen A., Rozenboom L., Stafford K., Weigele P., and Imgram V. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. 101 (2004) 14326-14332
44. Cairo C.W., Strzelec A., Murphy R.M., and Kiessling L.L. Affinity based inhibition of β-amyloid toxicity. Biochemistry 41 (2002) 8620-8629
45. Ritchie C., Bush A., and Masters C. Metal protein attenuating compounds and Alzheimer's disease. Expert Opin. Investig. Drugs 13 (2004) 1585-1592
46. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., De Luigi A., Vergani C., and De Simoni M. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and β-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 24 (2004) 4181-4186